samedan logo
 
 
 
spacer
home > ebr > spring 2008 > collaborate to innovate
PUBLICATIONS
European Biopharmaceutical Review

Collaborate to Innovate

Heather Fraser at the IBM Institute for Business Value discusses the importance of establishing a strong basis for biopharmaceutical collaborations, and explores the ways to ensure that they work for the life of the alliance

Biopartnering the sourcing, formation and management of alliances is now a multi-billion dollar business. Between 2004 and 2006 the number of alliances remained fairly constant, but their value tripled from US$30 billion to US$90 billion according to data from Recombinant Capital (1). Some US$30 billion worth of new deals were announced in 2006 alone. US biotech companies still dominate the industry, and European firms remain the preferred partners of those operating outside North American borders, according to recent research by Datamonitor (2). But the Asian biotech sector is also expanding rapidly, as changing regulations and better access to large patient populations make the region a more attractive place in which to conduct Phase I trials (3).

Given the rising value and increasing geographic spread of the biopartnering market, the ability to create successful alliances is becoming vital. In 2006, we conducted our fourth survey of biotech and pharmaceutical companies, along with Silico Research, to identify the key alliance-making trends (4). Our survey draws on the responses of 312 individuals from 235 companies. Seventy-four per cent work for biotech companies and 26 per cent for pharmaceutical companies. Fifty-two per cent are based in the US, reflecting the composition of the sector by market share.

EMERGING TRENDS IN BIOPARTNERING

The results of the 2006 survey confirm a troubling trend that first emerged in 2000. Despite the maturing of the biopartnering market, biotech companies reported that 52 per cent of the alliances in which they had participated during the previous five years failed to live up to their expectations. This is marginally better than the situation at the start of the decade, when the failure rate was 59 per cent but it is hardly encouraging.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Heather Fraser is a Pharmacist with over 20 years of industry experience and has held positions within R&D, consultancy and community pharmacy. Heather is currently the global leader of the Life Sciences & Pharmaceuticals team at the IBM Institute for Business Value.
spacer
Heather Fraser
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers
 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement